Ambrilia’s peptide for metastatic prostate cancer, Phase I/II results
Ambrilia, a Montreal company, said today that results of a Phase I/II trial of PCK3145 in patients with metastatic prostate cancer show that the drug, a small molecule peptide, slows tumor doubling time..
Previously, detailed Phase I results were presented at ASCO and are online: Slovin, S., et al. Phase I trial results of PCK3145 in patients with castrate metastatic prostate cancer: the US experience. ASCO Prostate Cancer – San Francisco, California, U.S.A., February 2006.